Solid tumour growth is dependent on the induction of their own blood supply by inducing a proangiogenic state in the tissue environment, regulating this balance between proangiogenic growth factors and antiangiogenic inhibitors (Folkman, 1985 (Folkman, , 1995 Boehm et al, 1997) . One growth factor that has been shown to be an effective target for antiangiogenic therapy (AAT) is vascular endothelial growth factor-A (VEGF-A). Inhibition of VEGF by humanised monoclonal antibodies has been shown to be effective in increasing the median survival in metastatic colorectal cancer (CRC) when combined with chemotherapy (Hurwitz et al, 2004) .
Vascular endothelial growth factor-A is generated by alternative splicing from eight exons within the VEGF-A gene. All isoforms contain exons 1 -5 and the terminal exon, exon 8. Exons 6 and 7, which encode heparin-binding domains, can be included or excluded. This gives rise to a family of proteins termed according to their amino-acid number, VEGF 165 , VEGF 121 , VEGF 189 and so on. Exon 8, however, contains two 3 0 splice sites in the nucleotide sequences, which can be used by the cell to generate two families of isoforms with identical length, but differing C-terminal amino-acid sequences (Bates et al, 2002) . VEGF xxx , the proangiogenic family of isoforms, is generated by use of the most proximal sequence in exon 8 (resulting from inclusion of exon 8a). The more recently described VEGF xxx b isoforms are generated by the use of a distal splice site, 66 bp further along the gene from the proximal splice site. This results in splicing out of exon 8a and the production of mRNA sequences that encode the VEGF xxx b family (Bates et al, 2002) . The two resultant families of proteins are of the same length, but with different carboxyl termini. VEGF 165 b was the first of these exon 8b-encoded isoforms identified and subsequent studies demonstrated the existence of VEGF 121 b, VEGF 183 b, VEGF 145 b (Perrin et al, 2005) and VEGF 189 b (Miller-Kasprzak and Jagodzinski, 2008) .
The functional consequences of this altered C terminus are that VEGF 165 b homodimers compete with VEGF 165 homodimers for binding to their principal receptor, VEGFR-2, at a one-to-one ratio and inhibit endothelial cell proliferation and migration in culture (Woolard et al, 2004; Cebe Suarez et al, 2006) . VEGF 165 b blocks VEGF 165 -driven angiogenesis in vivo in the rabbit, rat (Woolard et al, 2004) , mouse and chick (Cebe Suarez et al, 2006) , and human malignant melanomas consisting of cells overexpressing VEGF 165 b and cells expressing VEGF 165 grow slower in nude mice than those consisting of cells expressing VEGF 165 alone. Recombinant human VEGF 165 b is also antiangiogenic in hypoxia-driven angiogenesis in the eye (Konopatskaya et al, 2006) .
Although VEGF has been shown to be critical in CRC by inhibition studies, the expression of VEGF in CRC has not been investigated using tools that distinguish between the proangiogenic VEGF xxx isoforms and the antiangiogenic VEGF xxx b isoforms. The vast majority of studies have measured total VEGF levels in plasma, tumours or serum using commercially available antibodies that do not distinguish between pro-and antiangiogenic isoforms, as commercial enzyme-linked immunosorbent assays (ELISAs) detect VEGF xxx b isoforms. Furthermore, it is not known whether the VEGF xxx b isoforms are able to slow or reduce tumour growth if they are highly expressed. To determine whether this antiangiogenic isoform family is expressed in CRC, and how that expression may be regulated, this study compares the balance of expression of the VEGF xxx b family of isoforms in human CRC with paired normal colonic mucosa samples and show how the expression of VEGF xxx b and VEGF xxx is altered during the malignant transformation of colonic adenoma cells in vitro. Furthermore, to determine whether this balance has the potential to regulate tumour growth rates, we have measured VEGF 165 b functional effects on colon carcinoma growth in animal models where the tumour growth was VEGF-dependent. Furthermore, we assess whether bevacizumab either specifically binds VEGF xxx (proangiogenic) isoforms, or also has cross-reactivity with antiangiogenic VEGF 165 b and whether it inhibits VEGF 165 bexpressing tumours.
MATERIALS AND METHODS

Human tissue samples
Paired colon samples were from partial colon resection for carcinoma. Samples were obtained by taking biopsies of the fresh specimen from a nonnecrotic central portion of the tumour and from a peripheral part of the macroscopically normal colonic epithelium (n ¼ 18 pairs). Samples were collected with Local Ethics committee approval. The mean patient age was 71.5 (range 58 -80) years, with 62% male subjects and Duke's staging as follows: 6.7% A, 46.7% B and 46.7% C. Biopsies were immediately frozen in liquid nitrogen and then stored at À801C until processed. Biopsies were frozen in liquid nitrogen again immediately prior to manual slicing with a sterile blade. The mass of each tissue was recorded, and samples were homogenised and mRNA and protein extracted as described below.
Expression analysis
For each of eight pairs of samples, mRNA was extracted from approximately 200 mg of tissue (Chomczynski and Sacchi, 1987) and reverse transcribed as previously described (Bates et al, 2002) . The cDNA was amplified using primers complementary to VEGF exon 7 and the 3 0 -UTR downstream of exon 8b, as previously described (Bates et al, 2002) . The products were subjected to standard agarose gel electrophoresis and ethidium bromide staining. Protein was extracted from approximately 250 mg tissue, from 18 pairs of samples, resolved by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred and immunoblotted as previously described (Woolard et al, 2004) . Briefly, membranes containing recombinant human VEGF 165 and/or VEGF 165 b protein (50 ng of each) and protein samples extracted from colon (100 mg of each) were probed with mouse anti-VEGF xxx b IgG (2 mg ml À1 A56/1; R&D Systems, cat no. MAB3045) (Woolard et al, 2004) or rabbit anti-VEGF IgG (1 mg ml À1 A-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and detected with horseradish peroxidase-conjugated stabilised goat anti-mouse or anti-rabbit IgG (1/7000; Pierce Biotechnology, Rockford, IL, USA). Visualisation of protein bands was achieved with SuperSignal West Femto Maximum Sensitivity Substrate Kit (Pierce Biotechnology).
Quantitative RT-PCR
Quantitative PCR assays were carried out on cDNA generated as above. An exon 7b forward primer and a 3 0 -UTR primer (both pan-VEGF quantitative polymerase chain reaction (Q-PCR) from Primer Design, Southampton, UK) or an exon 7a forward primer 5 0 -TTGCTCAGAGCGGAGAAAGC-3 0 and a reverse primer specific for exon 8a that did not detect VEGF xxx b isoforms 5 0 -TCACCG CCTCGGCTTGTCACAT-3 0 were used. Reactions were performed using a SmartCyclerII (Cepheid, Sunnyvale, CA, USA) q-PCR machine, with 25 ml reaction volumes comprising 12.5 ml Quantitect SYBRgreen 2 Â master mix (Qiagen, Crawley, UK), 1 ml cDNA and 1 ml primer mix cycled at 951C for 15 min followed by 50 cycles of 601C for 30 s, 721C for 60 s, 791C for 15 s (reading) and 951C for 30 s. A melt curve was then performed by ramping the temperature from 60 to 951C at 0.21C per second, reading throughout. DNA standards used were VEGF 165 b or VEGF 165 cloned into pcDNA3, or oligonucleotides containing the full sequence between the primers (Primer Design). Figures 1A and B show examples of the reverse transcriptionpolymerase chain reaction (RT-PCR) curves for VEGF 165 b and VEGF 165 templates respectively using pan-VEGF primers. Figure 1C shows the standard curve generated from cycle threshold for the two templates, showing that there was no difference in the standard curves (n ¼ 3). Thus the efficiency of amplification of the two templates is not different. Figure 1D shows the amplification curves for the exon 8a primers using the VEGF 165 sequence as a template (VEGF 165 b template did not result in amplification until 18 cycles later than equivalent VEGF 165 concentration). Total VEGF and VEGF xxx copy numbers were calculated for each sample using the calibration curve shown in Figure 1E . The difference between the total VEGF and the VEGF xxx copy number was assumed to be the VEGF 165 b copy number.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraffinembedded normal colonic mucosa, obtained with local ethics committee approval from archival material as previously described (Woolard et al, 2004) . Sections were stained with either mouse monoclonal anti-VEGF xxx b IgG (8 mg ml À1 ; R&D Systems, cat no. MAB3045) or 5 mg ml À1 mouse anti-VEGF IgG (Santa Cruz; SC-7269) or a normal mouse IgG (Sigma Aldrich, Gillingham, UK; I8765), as a negative control.
ELISAs pan-VEGF mouse capture antibody (0.1 mg) (Duoset VEGF ELISA DY-293; R&D Systems, Minneapolis, MN, USA) diluted in 1 Â phosphate-buffered saline (PBS) (pH 7.4) was adsorbed onto each well of a 96-well sterile plate (Immulon 2HB Thermo Life Sciences, Basingstoke, UK) or, for the VEGF xxx b ELISA, 0.08 mg AF293-NA Goat anti-VEGF polyclonal IgG (R&D Systems), overnight at room temperature. The plates were washed three times between each step with 1 Â PBS-Tween (0.05%). After blocking with bovine serum albumin in PBS for 30 min at 371C, recombinant human VEGF 165 standards or VEGF 165 b (R&D Systems) diluted in blocking solution (ranging from 62.5 pg ml À1 to 2 ng ml À1 ) or protein sample was added to each well. After incubation for 30 min at 371C with shaking and three washes, 100 ml of biotinylated goat anti-human VEGF (50 ng ml À1 in blocking solution; R&D Systems) or a mouse monoclonal anti-VEGF xxx b-biotinylated IgG (clone 264610/1; R&D Systems) at 0.4 mg ml À1 was added to each well, and plates left for 30 min at 371C with shaking. Streptavidin-HRP (100 ml) (R&D Systems) at 1 : 200 dilution in PBS was added, plates left at room temperature for 20 min and 100 ml per well O-phenylenediamine dihydrochloride solution (Substrate reagent pack DY-999; R&D Systems) added, protected from light and incubated for 20 min at room temperature. The reaction was stopped with 100 ml per well 1 mol l À1 H 2 SO 4 (10276; BDH Chemicals, Poole, UK), and absorbance read immediately in an Opsys MR 96-well plate reader (Dynex Technologies, Chantilly, VA, USA) at 492 nm, with control reading at 460 nm.
Characterisation of the ELISA
We used both this antibody (MAB3045) and a separate antibody generated against the terminal nine amino acids of VEGF 165 b, raised by R&D Systems and biotinylated (clone 264610/1), to quantitate the relative levels of VEGF 165 b. Both VEGF 165 b antibodies were as sensitive as the commercially available VEGF ELISA (see Figure 2A) . The biotinylated 264610/1 antibody specifically detects VEGF 165 b, is accurate down to below 62.5 pg ml À1 VEGF 165 b and does not detect VEGF 165 , even at 4 ng ml À1 in an ELISA ( Figure 2B ). Both antibodies were used to determine the amount of VEGF xxx b in human tissues from pancreatic islets, placenta, lung, colon and prostate. The two ELISAs did not differ in their results (e.g., colon tissue, 130±40 pg mg À1 MAB3045 ELISA 128±20 pg mg À1 clone 264610/1 ELISA, N ¼ 18). The biotinylated 264610 ELISA was used to quantitate the amount of VEGF in tissue samples, as it was more sensitive, a simpler procedure, could use commercially available capture antibodies and the protocol was most comparable to the commercial VEGF DuoSet ELISA. To determine whether VEGF 165 could interfere with this VEGF 165 b ELISA, serial dilutions of rhVEGF 165 were assayed. As seen in Figure 2B , there was no significant change in OD values by the addition of rhVEGF 165 as high as 4000 pg ml À1 , indicating that the VEGF xxx b ELISA specifically detects VEGF 165 b, and is not affected by the conventional VEGF isoform, VEGF 165 . To determine whether commercially available ELISAs also detected VEGF 165 b, we carried out a VEGF ELISA using increasing concentrations of VEGF 165 b. Figure 2C shows that increasing concentrations of VEGF 165 b were detected by the R&D Duoset kitthe most widely used ELISA. Interestingly, this ELISA detects VEGF 165 b at a lower affinity than VEGF 165 . The ratio of the slopes is 0.42±0.004 or 42±0.4%. To confirm this, we used VEGF 165 b generated from two different sources -R&D Systems and an inhouse production (both proteins were quantitated by Bradford Assay). The R&D Duoset Kit (DY293B) is a second generation ELISA introduced in 2004. We are unaware of published information on sFlt-1 interference in the current DuoSet kit. Figure 2C shows that increasing concentrations of sFlt-1 did not affect the pan-VEGF ELISA at least up to 2000 pg ml À1 VEGF. With the previous ELISA, VEGF 165 b levels were detected at 100% of VEGF 165 , indicating that the previous ELISA kit had the same affinity for both isoforms. To ensure that this was due to a difference in affinity of the antibodies for the two isoforms, we carried out surface plasmon resonance analysis of binding coefficients.
Surface plasmon resonance
To compare the binding affinities of VEGF 165 and VEGF 165 b to the pan-VEGF antibody used in the R&D Duoset detection kit, we amine-coupled the latter to a CM5 sensor chip (Biacore AB, Uppsala, Sweden) to an immobilisation level of 630 response units (RU). To compare the binding affinities of VEGF 165 and VEGF 165 b to bevacizumab, the latter was amine-coupled to a CM5 sensor chip (Biacore AB) to an immobilisation level of 580 RU. The coupling was performed using EDC/NHS and 1 mol l À1 ethanolamine (Biacore) as per the manufacturer's instructions, with the bevacizumab dissolved in 10 mmol l À1 sodium acetate (pH 4.5). A blank reference cell was formed by the same activation and deactivation process involved in amine coupling without adding antibody. Samples containing VEGF 165 or VEGF 165 b diluted in HBS-EP sample buffer (Hepes-buffered saline with EDTA and P20 surfactant, Biacore AB) were then run at twofold serial dilutions from 180 nmol l À1 down, in random order in duplicate. Injection was performed at 30 ml min À1 for 3 min, followed by 6 min of buffer only, for monitoring of dissociation. Regeneration between each interaction was performed by injection of 4 mol l À1 MgCl 2 at 20 ml min À1 for 40 s, followed by a 2-min period of stabilisation before the next injection. Figure 3A shows the binding curves of VEGF 165 to the RnD detection antibody and Figure 3B shows binding of VEGF 165 b to the same antibody. The RnD detection antibody had a higher association coefficient for VEGF 165 than VEGF 165 b and a lower dissociation coefficient for VEGF 165 than VEGF 165 b ( Figure 3C ), resulting in an affinity of 602 pM for VEGF 165 , but 3.98 nM for VEGF 165 b, an B6.6-fold difference in affinity, indicating that the underestimation of the commercial ELISA for VEGF 165 b was due to a difference in affinity for the antigen.
The actual VEGF concentrations (VEGF total ) in human tissue are the sum of VEGF xxx and VEGF xxx b.
The commercially available pan-VEGF ELISA has a lower affinity for VEGF 165 b than for VEGF 165 by 42%. Therefore the measured VEGF levels (VEGF measured ) in the commercially available ELISA are the sum of VEGF 165 and 42% of VEGF 165 b.
VEGF measured ¼ VEGF xxx þð0:42ÂVEGF xxx bÞ Therefore;
We used the above correction to estimate tissue concentration of VEGF xxx b and its relative proportion of total VEGF.
Adenoma-carcinoma cell VEGF expression
Colonic adenoma cells (AAC1) and their in vitro-derived carcinoma cells (10C) were kindly donated by Professor C Paraskeva (Williams et al, 1990) . The adenoma cells are a non-tumour-forming clonogenic variant of the PC/AA cell line derived from a polyp from a patient with familial adenoma polyposis (Paraskeva et al, 1988) . The cells were cultured to 100% confluence in Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum, 1% penicillin/streptomycin and 0.2% Actrapid insulin (Novo Nordisk, Crawley, UK). Protein was extracted from confluent cells in fresh media as above cells were placed in a hypoxic chamber (Billups-Rothenburg, Del Mar, CA, USA) for 5 min at 20 l min À1 with 5% CO 2 /nitrogen gas mixture (BOC) and incubated at 371C. The gas was changed twice per day. 
In vivo tumour model
LS174t human colon carcinoma cell lines were used (ECACC, Salisbury, UK) (Yuan et al, 1996; Lee et al, 2000) . Cells were transfected with 1 mg of purified plasmid pcDNA3 either as empty vector, with VEGF 165 , VEGF 165 b, or both VEGF 165 and VEGF 165 b vectors, using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's instructions. Cells were selected using geneticin (500 mg ml À1 ). Conditioned media were analysed by ELISAs for VEGF and VEGF xxx b production per cell per 24 h, to confirm expression levels of VEGF isoforms. A total of 2 Â 10 6 cells were injected subcutaneously into the lumbar region of nude mice (six per group unless otherwise stated). Mice were then monitored every 2 -3 days and tumour length and width measured. When the first tumour reached 16 mm in maximum diameter, all mice were killed. Tumour volumes were calculated according to the formula (length Â width Â (length þ width)/2). Injections, measurements and analysis were all carried out with the investigators blinded to group.
Cytotoxicity
Measurement of the cell-cytotoxicity effects of blocking VEGF isoforms was performed using a lactate dehydrogenase (LDH) assay following exposure of the cells to various antibodies and RTKIs as described in the results. Cells were grown to 90 -100% confluence in 96-well plates prior to treatment in serum-free medium, against which treatment was compared. A Cytotox 96 Non-Radioactive Cytotoxicity Assay (Promega Corp, Madison, WI, USA, no. G1780) was used according to the manufacturer's instructions.
Statistics
Means and standard errors are given unless stated otherwise. Tumour volumes, cell cycle parameters and apoptosis were compared by one-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc test. Tumour growth curves were fitted by nonlinear regression using an exponential curve fit in Prism. Doubling times were calculated from 0.69 k À1 , and are given as mean (95% confidence intervals (CI)), and curve-fitting parameters compared using an F-test. Analysis of ELISA results was performed using Wilcoxon's signed matched ranks at 95% significance level (two-tailed). out on eight pairs of samples. Reverse transcription-polymerase chain reaction gave two bands, one at B135 bp, consistent with VEGF 165 b or VEGF 189 b, and one at B200 bp, consistent with VEGF 165 and VEGF 189 . This size difference was due to the splicing out of exon 8a in the VEGF xxx b family, resulting in the shorter mRNA (although exon 8b is present in the mRNA of the VEGF xxx family, a stop codon in exon 8a prevents its translation). VEGF xxx and VEGF xxx b mRNA expression was detected in both normal and tumour tissue ( Figure 4A ).
RESULTS
VEGF mRNA is differentially spliced in colon cancer
Quantitative PCR on mRNA extracted from seven pairs of colorectal normal and tumour tissue demonstrated that the VEGF xxx mRNA copy number was only 9.1±2.8% of the total VEGF level in normal tissues, indicating that VEGF xxx b species form more than 90% of the mRNA. There was an increase in copy number of all VEGF isoforms from 5±2.2 to 11±3.5 Â 10 3 copies per mg of tissue ( Figure 4B ). This upregulation was specific for the VEGF 165 isoform (0.18 ± 0.32 to 6.0 ± 2.6 Â 10 3 copies per mg, Figure 4C , Po0.01, ANOVA), and not for the VEGF 165 b isoform (4.8±2.2 to 5.6±2.0 Â 10 3 copies per mg, Figure 4D ), such that in cancers, 45 ± 13% of the VEGF mRNA was VEGF 165 .
VEGF 165 b and VEGF 121 b protein are expressed in normal and cancerous colon
To determine whether protein expression of VEGF xxx b isoforms was present in normal and tumour tissues, western blotting and ELISA were carried out using antibodies specific to VEGF 165 b and antibodies that do not distinguish between isoforms. The previously characterised anti-VEGF 165 b antibody (R&D Systems, cat no. MAB3045) demonstrates highly specific binding to recombinant human VEGF 165 b but not to recombinant human VEGF 165 (Pritchard-Jones et al, 2007) . Figure 5A shows that both VEGF 121 b and VEGF 165 b were expressed in both normal colonic mucosa and in carcinomas as detected by western blotting. To determine which cells in colonic epithelium expressed the VEGF xxx b isoforms, we used immunohistochemistry to stain the normal colon samples. Figure 5B shows that VEGF xxx b was highly expressed in colonic epithelial cells of the brush border (especially cells at the apex of the villi), cells within the lamina propria with plasma cell morphology and goblet cells. Staining of sections with the VEGF antibody that recognises all VEGF isoforms (including VEGF xxx b isoforms, Figure 5C ) showed that VEGF was expressed in all the places where VEGF 165 b staining was apparent. Nonspecific isotype control IgG did not stain ( Figure 5D ).
Increased VEGF protein levels in cancer are restricted to the angiogenic isoforms
To determine whether the previously reported increase in VEGF expression (Ellis et al, 2000; Reinmuth et al, 2003) in CRC was due to changes in VEGF xxx b or VEGF xxx , the levels of VEGF and VEGF xxx b were determined by ELISA and isoform-specific ELISA respectively. Total VEGF was significantly upregulated in CRC (288 ± 48 pg VEGF per mg total protein) compared to normal colon (122±23 pg mg À1 , n ¼ 18; Po0.01, Wilcoxon Figure 5E ). VEGF xxx b concentrations, however, were no different in tumour extracts (160 ± 50 pg mg À1 ) than in controls (130 ± 23 pg mg À1 ; P ¼ 0.96, Figure 5F ). Since the total VEGF is the sum of the proand antiangiogenic isoforms, the level of VEGF xxx expression was calculated in these samples. The mean VEGF xxx concentration in normal mucosa was not significantly different from zero. In CRC tissue, however, the mean VEGF xxx level was 128 ± 53 pg per mg total protein, indicating that the difference in total VEGF expression was due to an upregulation in VEGF xxx production alone. Thus, there was a shift from predominantly VEGF xxx b protein in controls to VEGF xxx in CRC (mean±s.e.m. ratio VEGF xxx b/total VEGF: 112±12% in controls, 59±12% in tumours; Po0.001 paired t-test). Figure 5G shows that the ratio of VEGF xxx to VEGF xxx b in the tumours was highly variable with some patients having no excess of VEGF xxx , and others up to 57-fold excess of VEGF xxx . There was no relationship between Dukes' staging and VEGF xxx b concentration or proportion (P ¼ 0.75; one-way ANO-VA, data not shown).
The switch in expression is part of the malignant transformation program
As VEGF expression is predominantly proangiogenic in CRC and predominantly antiangiogenic in normal colonic epithelium, cell lines at different stages of the malignant transformation may reflect this. Cells along the adenoma-carcinoma sequence, grown in 100% confluent monolayers, were assayed for VEGF expression as shown in Figure 6 . Although the total VEGF expression increased along the adenoma-carcinoma sequence, the degree to which it did so was very variable ( Figure 6A ) and only the LS174t cells demonstrated a significant such increase. In addition, the VEGF xxx b expression was reduced in the carcinoma cells compared to the adenoma cells, but this only reached significance in the HT29 cell line ( Figure 6B) . Overall, the effect of a shift from anti-to proangiogenic VEGF expression predominance in CRC cell lines was due to a combination of reduced VEGF xxx b expression and increased VEGF xxx expression, resulting in a shift from 82 ± 10% VEGF xxx b in adenoma cells to between 5.7±0.3 and 53±5.8% in the carcinoma cell lines (Po0.0001, one-way ANOVA, Figure 6C ). There was thus a predominance of VEGF xxx b in this adenoma cell line, and a variable switch towards predominance of VEGF xxx in the colonic carcinoma cell lines.
To test whether hypoxic upregulation of VEGF expression induced a switch in the relative expression of pro-and antiangiogenic VEGF required the use of cell lines that produced predominantly VEGF xxx b in normoxia, such as AAC1 and 10C. The exposure of the AAC1 cells to hypoxia resulted in a switch from predominantly antiangiogenic VEGF xxx b (82 ± 10% VEGF xxx b) to predominantly proangiogenic VEGF xxx (65±1% VEGF xxx ; Po0.01, Figure 6D ). This change in the AAC1 cells was due to an upregulation in the proangiogenic isoforms of VEGF, since total VEGF increased (Po0.01, Table 1 .
Proliferation of LS174t cells after transfection with VEGF 165 , VEGF 165 b, both or control vector was measured by flow cytometry. Histogram analysis of propidium iodide-labelled cells showed that there was no significant difference between the cell cycle stage of the groups (control 79±2.3%, VEGF 165 80±3%, VEGF 165 b 83 ± 5% and VEGF 165/165 b 77 ± 0.7% in G 0 /G 1 ; P40.1). Apoptosis and necrosis were also measured by dual PI/Annexin V staining. There were no significant differences between the four groups (data not shown). Figure 7C ). Overexpression of VEGF 165 in LS174t cells resulted in large, vascular tumours ( Figure 7D ). However, injection of cells expressing both VEGF 165 and VEGF 165 b resulted in smaller, paler tumours than VEGF 165 alone (Po0.001, Figures 7E and F) . VEGF 165 b tumours (0.33 ± 0.22 cm 3 ) were significantly smaller than the VEGF 165 -expressing tumours (1.61±0.57 cm 3 ; Po0.001) at 15 days. Exponential curve fitting to the tumour growth curves was used to calculate the doubling time of the tumour groups. The mean (95% CI) doubling times for pcDNA3, VEGF 165 overexpression and VEGF 165/165 b overexpression were 2.1 (1.9 -2.4), 1.9 (1.9 -2.1) and 2.4 (2.2 -2.6) days respectively. In comparison, the doubling time for VEGF 165 b overexpression was 3.0 (2.5 -3.6) days, which was statistically significantly different (Po0.001) from the other groups. After excision, tumour sections were stained with haematoxylin and eosin, and areas of necrosis quantified ( Figure 7G ). VEGF 165 b-expressing tumours had significantly greater areas of necrosis compared with other groups (Figure 7H ; Po0.05 ANOVA).
Bevacizumab can bind VEGF 165 b
To determine whether bevacizumab bound VEGF 165 b, a western blot of recombinant human VEGF 165 and VEGF 165 b was carried out by immunodetection with bevacizumab and secondary antibodies to human IgG ( Figure 8A ). Bevacizumab appeared to detect efficiently recombinant human VEGF 165 b. To determine the efficiency of binding, and its affinity for VEGF 165 b, we carried out Biacore analysis of bevacizumab covalently bound to a surface plasmon resonance sensor. Figure 8B shows the association and disassociation kinetics of VEGF 165 , and Figure 8C those for VEGF 165 b across this chip ( Figure 8D ). The ratio of these two gives the overall affinity (K D ). The K D was similar for VEGF 165 (2.5 nM) and VEGF 165 b (6.8 nM).
VEGF 165 b inhibits the effect of bevacizumab
To determine whether the effect of bevacizumab on tumour growth was dependent on VEGF 165 b expression, nude mice were injected with either VEGF 165 b-transfected LS174t colon cancer cells expressing 95% VEGF 165 b (n ¼ 14), or control LS174t cells expressing 94% VEGF 165 (n ¼ 12). Twenty-four hours after tumour cell injection, bi-weekly treatment with 50 mg bevacizumab or saline was started, and tumour sizes measured every 3 -4 days. Figure 9A shows that bevacizumab significantly inhibited the growth of VEGF 165 -expressing colon cancer cells (Po0.05) within 15 days. Figure 9B shows that even after 35 days of treatment, bevacizumab had no effect on tumour growth in cells expressing predominantly VEGF 165 b. To determine whether the effect of bevacizumab on previously established tumours was modified by VEGF 165 b, cells were injected as before, and tumours allowed to grow to 4 mm in diameter before treatment with bevacizumab as above. Figure 9C shows that bevacizumab inhibited the growth of established tumours compared with saline treatment (Po0.05), whereas Figure 9D shows that it did not affect the growth of VEGF 165 b-expressing tumours. Figure 9E shows that VEGF 165 bexpressing tumours grew faster than those not expressing VEGF 165 b when treated with bevacizumab (Po0.05).
VEGF inhibition is toxic to colonic epithelial cells
VEGF 165 b is strongly expressed in normal colonic tissue and by AAC1 colonic adenoma cells and has been shown to be cytoprotective in renal epithelial cells. Therefore, the sequestration of VEGF 165 b by addition of either a specific anti-VEGF xxx b antibody or a more general anti-VEGF antibody could be cytotoxic. To explore this, AAC1 adenoma cells (normally express B85% of their VEGF as VEGF 165 b) were treated with either an anti-VEGF 165 b-specific antibody (R&D Systems, cat no. MAB3045) or bevacizumab at increasing doses for 48 h. Cytotoxicity was measured by assaying supernatant for lactate dehydrogenase. Figure 10A shows that VEGF 165 b inhibition was toxic to AAC1 cells in a dose-dependent manner, increasing the cytotoxicity by 14.4±1.1-fold (Po0.001). Bevacizumab also significantly increased cytotoxicity 4.9 ± 0.5-fold (Po0.001). A nonspecific IgG (1 mg ml À1 ) resulted in a modest 2.2 ± 0.25-fold increase in cytotoxicity over baseline in AAC1 cells (Po0.01). Much smaller increases in cytotoxicity were seen when LS174t colonic carcinoma cells were treated with the anti-VEGF 165 b antibody (4.0 ± 0.35-fold) or bevacizumab (3.2 ± 0.6-fold) ( Figure 10B , no increase seen with nonspecific IgG). To confirm that the cytotoxicity effects of anti-VEGF antibodies were due to inhibition of VEGF xxx b, the effects of supplementing the media with rhVEGF 165 b were measured ( Figure 10C ). Addition of 40 ng ml À1 rhVEGF 165 b protein abolished cytotoxicity induced by the VEGF 165 b antibody (Po0.01, one-way ANOVA).
To evaluate whether the VEGF 165 b required for AAC1 cell survival was acting through VEGFR1 or VEGFR2, cells were treated with receptor tyrosine kinase inhibitors to selectively inactivate each of these receptors. Selective inhibition (Glass et al, 2006) of either VEGFR1 (10 nM SU5416) or VEGFR2 (200 nM ZM323881) was not toxic to the AAC1 cells ( Figure 10D ), but combined inhibition of both receptors induced a significant increase in cytotoxicity (1.8±0.29-fold; Po0.05, one-way ANOVA), an effect that could be rescued by the addition of 100 ng ml À1 of either rhVEGF 165 or rhVEGF 165 b protein.
DISCUSSION
Vascular endothelial growth factor has been identified in thousands of studies as being altered in tumours, and able to affect tumour growth. VEGF 165 was originally identified from tumours and tumour cells, showed angiogenic and propermeability activity and was generated from the sequence now described as exon 8a. In 2002, we described VEGF 165 b, encoded by an alternative sequence in exon 8 (exon 8b), resulting in a protein of identical length but different amino-acid sequence to that encoded by exon 8a. This different C terminus is also found in other VEGF isoforms, resulting in a family of VEGF xxx b splice variants (Perrin et al, 2005) that is expressed in many normal tissues and mirrors the conventional, angiogenic VEGF xxx isoforms. 
VEGF 165 b is expressed in colonic mucosa
Homodimeric VEGF 165 b is a competitive antagonist of VEGFR2, binding to it with affinity equal to that of VEGF 165 (Woolard et al, 2004) . Moreover, VEGF 165 b is not angiogenic, and can act as an antiangiogenic agent in VEGF-mediated angiogenesis, such as in the eye and in the mesentery (Woolard et al, 2004) . We show here that these antiangiogenic isoforms of VEGF are expressed as mRNA and protein in both normal colonic epithelial cells and colonic carcinomas. Not only is their expression dominant in normal colonic epithelium, but also remains relatively constant in the carcinomas. Many previous studies have identified VEGF upregulation in colon carcinomas either without distinguishing between the two families of isoforms or by methods that only detect the proangiogenic isoforms. Previously described total VEGF levels seen in normal and CRC samples are similar to those described here (40 and 220 pg mg À1 , respectively ). However, this is a significant underestimate of total VEGF, as the commercially available ELISAs for VEGF have an affinity for VEGF 165 b of only 42% compared with VEGF 165 . Thus, a more accurate estimation of VEGF concentrations in tissues requires a correction for this affinity. Here we show that the measured amount of VEGF xxx , but not VEGF xxx b, is increased in CRC, supporting the idea that there is a proangiogenic switch involving upregulation of both VEGF overall and, crucially, of only the proangiogenic splice variants.
However, our results show that the VEGF 165 b levels in some tissues (approximately half of the normal samples) exceed those of the total VEGF levels, measured by the pan-VEGF ELISA, even after adjustment for the poor affinity of the pan-ELISA for VEGF 165 b. There are a number of possible reasons for this difference, although none has been clearly proven, mainly relating to the lack of accuracy of the commercial pan-VEGF ELISA when the VEGF xxx b isoforms are considered. These include ( (Perrin et al, 2005) , but the affinity of the ELISAs for these (particularly the commercially available pan-VEGF ELISA) has not been measured. If the affinity of the commercial pan-VEGF ELISA for VEGF 121 b or VEGF 121 was less than that for VEGF 165 b or VEGF 165 , then this would also result in an underestimate of the total VEGF levels. Finally, the soluble splice variant of VEGFR1 (sFlt-1) has been shown to inhibit detection of VEGF in previous commercially available pan-VEGF ELISAs (Maynard et al, 2003) . We showed that sFlt-1 does not interfere with the current R&D pan-VEGF ELISA, ruling this out as an explanation for the discrepancy, but other proteins, such as soluble VEGFR2, may affect binding. We show here that VEGF xxx b is localised to the same regions of the colonic mucosa as that previously thought to be for proangiogenic VEGF, the lamina propria (Griga et al, 2002) , goblet cells and glandular cells of the mucosa (Griga et al, 1999) and our findings for the pan-VEGF stain are consistent with this. The detection of the same cells by the antibody raised specifically against VEGF 165 b, as by an antibody to all VEGF isoforms, concurs with our ELISA findings that in normal colonic mucosa it is the VEGF xxx b isoforms that predominate. This has significant implications for interpretation of all previous studies investigating VEGF expression in the colon, not only for tumour studies (Hurwitz et al, 2004) , but also for collagenous (Griga et al, 2004) and ischaemic colitides (Okuda et al, 2005) .
Antiangiogenic VEGF tumour inhibition
The results here show that VEGF overexpression can alter the rate of human xenografted tumour growth in vivo and moreover that VEGF 165 b can antagonise the effects of VEGF 165 , thus confirming the role of the C terminus of VEGF in determining its function and the importance of the ratio of VEGF xxx b to VEGF xxx in the progression of tumour growth. The ability of AAT to inhibit xenografted tumour growth has been demonstrated previously (Kendall and Thomas, 1993; Kim et al, 1993; Kanai et al, 1998;  Wildiers et al, 2003) . The effectiveness of AAT has translated into the clinic with bevacizumab in the treatment of renal (Yang et al, 2003) , breast (Ramaswamy et al, 2006) and CRCs (Hurwitz et al, 2004) . Furthermore, the ability of VEGF 165 b to inhibit VEGF 165 -mediated angiogenesis in a rat mesenteric and rabbit corneal assay (Woolard et al, 2004) and mouse retinal angiogenesis assay (Konopatskaya et al, 2006) suggests that it may serve as a novel AAT agent. Consistent with this, we show here that the overexpression of VEGF 165 b in human CRC can inhibit tumour growth in vivo, further supporting the potential role of relative VEGF xxx b downregulation as part of the angiogenic switch in tumour progression. Furthermore, neither VEGF 165 nor VEGF 165 b overexpression alters the in vitro proliferation or apoptosis rates of cells, suggesting that the mechanism of action of VEGF in altering tumour growth rate is not through an autocrine pathway, but likely to be via its known antiangiogenic effects. Furthermore, the antagonistic effects of VEGF 165 b overexpression on tumour growth when co-overexpressed with the potent proangiogenic VEGF 165 and the increased tumour necrosis observed when VEGF xxx b was overexpressed further suggests that VEGF 165 b inhibits tumour growth through antiangiogenesis.
Bevacizumab binds VEGF 165 b
Bevacizumab binds to all the conventional isoforms of VEGF (Kim et al, 1992) via an epitope on the common region of the protein family, adjacent to the receptor-binding site (Muller et al, 1997) . In CRC, the response to bevacizumab is limited to a small subset of patients, approximately 11 -12%, but to date this subset has not been shown to be predictable (Jubb et al, 2006) . The results here show that the affinity of bevacizumab was similar for VEGF 165 and VEGF 165 b and concur well with the results by Presta et al (1997) . Thus the variability in response to bevacizumab could be explained by VEGF xxx b expression. The relative expression levels of the VEGF xxx isoforms in human colon carcinoma vary from only 27% of the VEGF xxx b isoforms to 60-fold excess, whereas in normal colon, we did not detect excess of VEGF xxx over VEGF xxx b. This can explain why in some patients bevacizumab could be a highly effective antiangiogenic agent -those in which the vast majority of the VEGF in their carcinomas is VEGF xxx (the proangiogenic family), whereas in most, those with significant VEGF xxx b expression, bevacizumab may be less effective. To date, no biomarkers have been identified that can predict response to bevacizumab (Ince et al, 2005; Jubb et al, 2006) . The differential response in the LS174t tumours to bevacizumab therapy in mice depending upon VEGF 165 b-to-VEGF 165 ratio shown here is suggestive of its role as a potential biomarker in CRC and possibly other cancers that are responsive to bevacizumab. It remains to be seen whether patients with high levels of VEGF 165 b respond poorly to bevacizumab, but this needs to be tested. Vascular endothelial growth factor has been shown to be a survival factor for several carcinoma types, including colon. Transfection of RKO colon cancer cells with short interfering RNA against the coding region of VEGF reduced cell proliferation by 67% (Mulkeen et al, 2006) . However, given that normal colonic epithelial cells produce principally VEGF xxx b and the toxicity of blocking VEGF xxx b in AAC1 adenoma cells, the autocrine role, may be predominantly due to VEGF xxx b in colonic epithelial cells, suggesting for the first time a physiologically active role of VEGF xxx b. Furthermore, the general anti-VEGF antibody bevacizumab was also cytotoxic to AAC1 cells, suggesting that bevacizumab could potentially have negative effects on normal colonic epithelium, which expresses high levels of VEGF xxx b. A life-threatening complication of bevacizumab therapy is gastrointestinal perforation, the cause of which is unknown (Hurwitz et al, 2004) , but could be due to its effects on survival of normal colonic epithelial cells, as suggested by the results shown here.
In summary, we show here that in normal colonic epithelium, the antiangiogenic isoforms form the majority of VEGF, and VEGF upregulation in CRC is unique to the proangiogenic isoforms. These results indicate that the role of VEGF in the normal function of the colonic mucosa may depend either on the function of VEGF xxx b, which is still unknown, or the effect of the balance between the isoforms. We also show that this switch appears to be an endogenous one to transformation, although environmental cues such as hypoxia can also induce the switch. Furthermore, VEGF 165 b inhibits both colorectal tumour growth (in a VEGFdependent manner) and the effect of bevacizumab on that tumour growth. We further show that bevacizumab binds VEGF 165 b and that VEGF 165 b is an autocrine survival factor for colonic epithelial cells. These results suggest that anti-VEGF therapy for CRC may be better targeted to patients with significant excess of proangiogenic isoforms over antiangiogenic isoforms, and that therapies that specifically target the proangiogenic isoforms may be more effective.
